Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...
Milestone Pharmaceuticals (MIST) announced the U.S. Food and Drug Administration, FDA, issued a Complete Response Letter, CRL, regarding its ...
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
Investing.com -- TD Securities downgraded Milestone (WA:MMD) Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that ...
Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a ...